APA (7th ed.) Citation

C, L. D., N, V., S, M., L, D., N, S., S, B., . . . E, K. (2025). COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network. Influenza and other respiratory viruses, 19(5), e70120. https://doi.org/10.1111/irv.70120

Chicago Style (17th ed.) Citation

C, Laniece Delaunay, et al. "COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network." Influenza and Other Respiratory Viruses 19, no. 5 (2025): e70120. https://doi.org/10.1111/irv.70120.

MLA (9th ed.) Citation

C, Laniece Delaunay, et al. "COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network." Influenza and Other Respiratory Viruses, vol. 19, no. 5, 2025, p. e70120, https://doi.org/10.1111/irv.70120.